Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
This is a Phase 3 trial to evaluate the efficacy and safety of 30 mg/kg intravenous (IV)
infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants
with Idiopathic Pulmonary Fibrosis (IPF). There is a 48-week randomized treatment phase
followed by an optional, open-label extension phase.